Company

PBD Biotech is announcing that is focusing its efforts on developing Actiphage as a rapid blood test for Human Tuberculosis (TB) and will be suspending its commercial Johne’s Testing Service.

Human tuberculosis is second only to Covid as the world’s most fatal infectious disease. PBD Biotech has developed a diagnostic with potential to revolutionise management of TB.

Innovation directed at an unmet market need can stimulate economic development if the value creation is kept within the local economy. The recent pandemic has shown the huge value of diagnostics and tuberculosis (TB), for which there are currently few...

PBD Biotech, developers of a phage-based diagnostic for tuberculosis, is moving to the next stage of its development. It is appointing Jane Theaker, of precision medicine company Kinomica, as the new CEO and bringing Commercial Director, Jonnie Yewdall, into a...

After growing PBD Biotech from start-up to international player in just three years, Dr Berwyn Clarke has decided to retire as CEO to make time for other business interests. He will remain on the diagnostics company’s Board of Directors.

PBD Biotech Limited is pleased to announce that its key technology patent has been granted by the European Patent Office.

Following PBD Biotech’s successful seed funding round, CEO Dr Berwyn Clarke spoke to Growth Business, the leading media portal for entrepreneurs, about the start-up’s strategic approach to securing the right investment for phage-based technology.